Food and Drug Administration v. Alliance for Hippocratic Medicine

Questions presented

SCOTUS records, cert granted 13 Dec 2023

1. This case concerns mifepristone, a drug that the U.S. Food and Drug Administration (FDA) approved in 2000 as safe and effective for terminating early pregnancies. The Fifth Circuit held that respondents-doctors and associations of doctors who oppose abortion-have Article III standing to challenge FDA's 2016 and 2021 actions with respect to mifepristone's approved conditions of use and that those actions were likely arbitrary and capricious. The court therefore affirmed the district court's stay of the relevant agency actions. The questions presented are:
2. Whether respondents have Article III standing to challenge FDA's 2016 and 2021 actions.
3. Whether FDA's 2016 and 2021 actions were arbitrary and capricious.
4. Whether the district court properly granted preliminary relief.

Opinion summary

Etalia.ai summary of the majority opinion

The case involved the Food and Drug Administration (FDA) and its approval of mifepristone, a medication used for medical abortions. The Alliance for Hippocratic Medicine challenged the FDA's decision, arguing that the agency did not adequately consider safety concerns associated with the drug. The Supreme Court was tasked with determining whether the FDA followed proper procedures in approving mifepristone and if it sufficiently addressed potential health risks. Ultimately, the Court upheld the FDA’s authority to approve drugs based on scientific evidence presented during clinical trials, emphasizing deference to expert agencies in matters involving complex scientific assessments. This decision reinforced regulatory standards set by federal agencies like the FDA when evaluating pharmaceuticals' safety and efficacy.